Article Versions Notes

Gil RJ, Kern A, Bojko K, Gziut-Rudkowska A, Vassilev D, Bil J. The Randomized, Multicenter, Open-Label, Controlled POLBOS 3 Trial Comparing Regular Drug-Eluting Stents and the Sirolimus-Eluting BiOSS LIM C Dedicated Coronary Bifurcation Stent: Four-Year Results. Biomedicines. 2024; 12(5):938. https://doi.org/10.3390/biomedicines12050938

Gil, Robert J., Adam Kern, Krystian Bojko, Aneta Gziut-Rudkowska, Dobrin Vassilev, and Jacek Bil. 2024. "The Randomized, Multicenter, Open-Label, Controlled POLBOS 3 Trial Comparing Regular Drug-Eluting Stents and the Sirolimus-Eluting BiOSS LIM C Dedicated Coronary Bifurcation Stent: Four-Year Results" Biomedicines 12, no. 5: 938. https://doi.org/10.3390/biomedicines12050938

Gil, R. J., Kern, A., Bojko, K., Gziut-Rudkowska, A., Vassilev, D., & Bil, J. (2024). The Randomized, Multicenter, Open-Label, Controlled POLBOS 3 Trial Comparing Regular Drug-Eluting Stents and the Sirolimus-Eluting BiOSS LIM C Dedicated Coronary Bifurcation Stent: Four-Year Results. Biomedicines, 12(5), 938. https://doi.org/10.3390/biomedicines12050938